FDA PMA
FDA Class 3
Approved
🇺🇸 United States
System, Colorectal Neoplasia, Dna Methylation And Hemoglobin Detection
PMA: P130017
·
Supplement: S057
·
Decision Jul 20, 2024
Classifications
1
FEI Numbers
11
Registration Numbers
11
Basic Information
- Device Name
- System, Colorectal Neoplasia, Dna Methylation And Hemoglobin Detection
- Trade Name
- COLOGUARD
- PMA Number
- P130017
- Supplement Number
- S057
- Device Class
- FDA Class 3
- Product Code
- PHP
- Generic Name
- System, colorectal neoplasia, DNA methylation and hemoglobin detection
- Medical Specialty
- Unknown
- Advisory Committee
- Pathology
- Decision
- Approved
- Decision Code
- APPR
- Decision Date
- July 20, 2024
- Date Received
- January 26, 2024
- Supplement Type
- Normal 180 Day Track No User Fee
- Supplement Reason
- Labeling Change - PAS
- Expedited Review
- N
Advisory Committee Statement
Approval for updating Cologuard labeling to include the completed Post-Approval study information.
Classifications
This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| PHP | System, Colorectal Neoplasia, Dna Methylation And Hemoglobin Detection | FDA class 3 | Unknown |